Isomorphic Labs Raises $5 Billion in Series C Funding Round
Key Facts
Isomorphic Labs announced on November 17, 2026, that it had raised $5 billion in a Series C funding round, providing new capital to support AI-driven drug development. The company said in its statement that it had raised the amount, without disclosing a valuation when it announced the round. Greenoaks and Sequoia Capital jointly led the financing, with participation from Andreessen Horowitz and other new investors. Alphabet also continued its significant investment in the company. The round included all existing investors, signaling a broader base of financial support for the company's research and development plans.
The existing investors that participated included Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. The new funding follows the Series B round the company announced on May 12, 2026, when it raised $2.1 billion led by Thrive Capital. About six months separate the two announcements, making the Series C a substantial follow-on financing in a short period. This sequence puts the size of the current round in the context of the funding the company secured before it, while the figure announced now remains $5 billion. Thrive Capital's participation in both the previous and current rounds links the two funding stages, as it was among the existing investors that took part in the new round.
The company plans to use the capital to expand its drug-design engine and models, as well as to broaden its work into new areas of biology. Its plans also include building an ecosystem of partners and developing its internal drug programs and programs pursued with other parties. Isomorphic Labs said its goal includes advancing drug candidates toward clinical trials, while that step remains a future stage in the development process. These priorities link the expansion of the company's research capabilities with moving candidate programs into more advanced stages. The funding gives the company resources to support internal work and external collaboration, according to the plans it announced.
The company announced two strategic collaborations with Eli Lilly and Novartis in January 2024, saying their potential value approached $3 billion, excluding royalties that might arise from future drug sales. In February 2025, Isomorphic Labs and Novartis expanded their collaboration by adding up to three research programs to its scope. The initial scope focused on discovering small-molecule therapeutics targeting three challenging targets. The expanded collaboration shows the partnership programs extending across different time periods, alongside the company's current emphasis on building an ecosystem of partners. The stated value of the two collaborations remains a potential estimate announced in 2024, separate from the funding amount the company announced in November 2026.
Before the round closed, Bloomberg reported on November 4, 2026, citing people familiar with the matter, that the proposed financing could value Isomorphic Labs at about $50 billion. The company did not include that valuation in its announcement that it had raised $5 billion. The round amount therefore remains the figure confirmed by the company, while the potential valuation appeared in Bloomberg's earlier report as an estimate attributed to its sources. The company's background includes its separation from Alphabet's Google DeepMind, as reported by Bloomberg. The current announcement follows that earlier coverage, with the company setting out the funding amount, investors and development plans without disclosing its valuation.